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patients undergoing CABG is limited by the lack of
sensitivity of ECG changes and by enzyme release from
noncardiac tissue.1
The aim of this prospective, randomized study was to
compare the use of antegrade crystalloid cardioplegia
(CCP) with antegrade cold blood cardioplegia (BCP) in
P revious studies have frequently used postoperativeelectrocardiographic (ECG) changes and the release
of cardiac enzymes, such as the MB isoenzyme of cre-
atine kinase (CK-MB) for assessing the adequacy of
myocardial protection during coronary artery bypass
grafting (CABG). The value of these markers in
Objective: The purpose of this study was to assess the efficacy of myocar-
dial protection, comparing antegrade crystalloid cardioplegia with cold
blood cardioplegia, in patients with preserved left ventricular function
who were undergoing elective first coronary artery bypass grafting.
Release of cardiac troponin I was used as a marker for the effectiveness
of myocardial protection. Methods: A consecutive series of 62 patients
were randomly assigned to receive crystalloid or blood cardioplegia.
Cardiac troponin I concentrations were determined in venous blood
samples before the operation, immediately after unclamping, at 6, 9, 12,
and 24 hours, and daily thereafter for 5 days. Results: Rising levels of tro-
ponin I were found in all patients. The time course and peak release
were similar in the crystalloid cardioplegia and the blood cardioplegia
groups. No patients in either group had electrocardiographic evidence
of perioperative myocardial infarction. Cardiac troponin I was able to
detect small areas of myocardial damage, not revealed by electrocardio-
graphy or creatine kinase MB release. Aprotinin administration was
associated with lower cardiac troponin I release in both groups. Cardiac
troponin I was lower in patients whose conditions did not require elec-
trical defibrillation after aortic unclamping, irrespective of cardioplegia
type. The presence of a main stem lesion was associated with higher car-
diac troponin I release only in the crystalloid cardioplegia group.
Conclusions: Antegrade cold blood cardioplegia is equally effective as
antegrade crystalloid cardioplegia in a randomized group of patients
with preserved left ventricular function who were undergoing elective
first coronary artery bypass grafting. Aprotinin administration resulted
in lower cardiac troponin I release, whereas electrical defibrillation was
related to a higher release irrespective of cardioplegia type. The pres-
ence of a main stem lesion resulted in higher cardiac troponin I release
in the crystalloid cardioplegia group. (J Thorac Cardiovasc Surg 1999;
118:452-9)
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patients with preserved left ventricular function under-
going first-time elective CABG.
Cardiac troponin I (CTnI) was used as a biochemical
marker for the adequacy of myocardial protection,
because of its high sensitivity and specificity.
Methods
Patient selection. From January 5 through April 14, 1998,
115 CABG operations were performed at the Virga Jesse
Hospital Hasselt by 2 staff surgeons (U.M. and M.H.). From
these operations, 62 consecutive patients (49 men and 13
women; mean age, 67 ± 7.7 years) agreed to participate in a
prospective, randomized trial comparing cold CCP with cold
BCP.
Exclusion criteria for this study were patients with single
vessel disease (n = 8; all treated with minimally invasive
direct coronary bypass [MIDCAB] procedures), patients with
poor left ventricular function (left ventricular ejection frac-
tion < 30%; n = 32), patients undergoing redo CABG surgery
(n = 11), and patients with concomitant heart valve disease.
Two patients were excluded because of refusal to sign an
informed consent form. Both cardioplegic techniques were
used by both surgeons. The study was approved by the insti-
tutional human experimentation committee, and written con-
sent was obtained from all patients.
Operative procedure. All operations were performed with
cardiopulmonary bypass, with ascending aortic cannulation, 2-
stage venous cannulation, and moderate hypothermia (32°C).
The left ventricle was vented by a catheter that was intro-
duced through the right superior pulmonary vein. 
In patients who had discontinued salicylic acid intake less
than 10 days before the operation, aprotinin was administered
according to the Hammersmith scheme. A loading dose of 2
million kallikrein inactivation units (KIU) was given before
sternotomy, followed by an infusion of 0.5 · 106 KIU/h until
the end of the operation. Additionally, 2 million KIU was
added to the priming volume.
The route of cardioplegia delivery was exclusively ante-
grade in both groups. 
Cardiac arrest was achieved by injecting an average of 750
mL of cardioplegic solution into the aortic root at 7°C imme-
diately after aortic crossclamping, to obtain a myocardial sep-
tal temperature of 10°C to 12°C.
The administration of the cardioplegic solution was pres-
sure controlled in both groups. An aortic root catheter was
inserted and attached to the cardioplegia line after deairing.
Aortic root pressure was continuously monitored through a
pressure line attached to a strain gauge. The cardioplegic
solution (crystalloid or blood) was infused into the root at a
pressure of 70 to 80 mm Hg. In the CCP group, flow rates of
250 to 300 mL/min per square meter were obtained, whereas
in the BCP group, flow rates were between 110 and 130
mL/min per square meter, because of the difference in vis-
cosity. In patients with severe ischemic disease, pressure was
sometimes allowed to rise above 80 mm Hg, not to reduce the
flow below 200 mL/min per square meter in the CCP group
or 100 mL/min per square meter in the BCP group. However,
the fact that it took longer to administer BCP did not signifi-
cantly affect the total duration of crossclamp time (46 ± 12
minutes [standard deviation] in the CCP group vs 47 ± 11
minutes [SD] in the BCP group).
An additional dose of 300 mL was reinjected after each dis-
tal anastomosis, except the last one. Myocardial protection
was completed by topical ice-cold water. Proximal anasto-
moses were completed on the beating heart with an aortic
partial occlusion clamp.
Cardioplegia groups. The composition of the CCP, the
BCP additive composition, and the approximate final BCP
composition are shown in Table I. BCP was made by adding
oxygenated blood from the pump to a modified additive com-
position in a ratio of cardioplegic solution/blood of 1:4, with
the Sarns conducer cardioplegia set 9457 (Sarns Inc/3M
Health Care, Ann Arbor, Mich), to obtain a final potassium
concentration similar to that of the crystalloid solution used.
Cardioplegic solution (750 mL) was infused initially; the
infusion (300 mL) was repeated after each distal anastomosis.
No warm controlled reperfusion protocol was used in the
BCP group, and the crossclamp was removed immediately
after the last distal anastomosis.
Measurements of cardiac marker proteins. Serial
venous blood samples were collected before the induction of
anaesthesia, immediately after aortic unclamping, at 6, 9, 12,
and 24 hours after unclamping, and daily thereafter for 5 days.
CTnI concentrations were measured by a specific
microparticle enzyme immunoassay developed by Abbott
Diagnostics (Abbott Laboratories, Abbott Park, Ill).
Each standard (purified CTnI) or sample was incubated
with microparticles coated with anti-TnI antibodies. An
aliquot of the reaction mixture was transferred to a glass fiber
matrix. Alkaline phosphatase–labeled anti-TnI antibodies
were allowed to bind to the microparticle complex. The sub-
strate 4–methylumbelleferyl phosphate was added, and the
fluorescent product, methylumbelleferone, was measured by
the assay. This assay, as opposed to most assays used previ-
ously, reflects the accurate quantification of both free and
complexed TnI.
Reliable immunologic detection of TnI is possible only
Table I. Cardioplegic solutions
Approximate 
BCP additive BCP final 
CCP composition* concentration
Sodium (mmol/L) 139 116 139
Potassium (mmol/L) 32 146 32
Magnesium (mmol/L) 14 68 14
Calcium (mmol/L) 2 2 2
Chloride (mmol/L) 153 363 153
Bicarbonate (mmol/L) 8 0 18
Hematocrit (%) 0 0 18
*The BCP is a mixture (4:1 dilution) of the oxygenated blood of the patient
and of a hyperkalemic crystalloid additive solution.
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when antibodies recognize both free TnI and TnI complexed
with other troponin components. It was shown that, in condi-
tions of myocardial damage, TnI is released in the blood-
stream not in free form but as a complex. Furthermore, from
observation of patients having a myocardial infarction, it
became clear that the ratio of total to free CTnI in the serum
varies in the course of observation and is different in serum
samples from different patients.2
CK-MB activities were measured after immunoinhibition
at 25°C by means of an N-acetylcysteine–activated, opti-
mized ultraviolet test from Merck (Darmstadt, Germany).
CK-MB was measured at 6 hours after operation and daily
thereafter. CK-MB levels above 6% were interpreted as indi-
cating perioperative myocardial infarction.
ECG. A 12–lead ECG was performed before the operation,
on admission in the intensive care unit, and then daily after
the operation for 5 days. All ECGs were read by one cardiol-
ogist, blinded to the study. Diagnostic criteria for periopera-
tive myocardial infarction were new Q waves of 0.04 mm or
more or a reduction in R waves of more than 25% in at least
2 leads.
Statistical analysis. For descriptive purposes (Table II),
the Wilcoxon rank sum test (in the case of continuous and
ordinal variables) and Fisher’s exact test (in the case of cate-
goric variables) were used when comparing the distribution
of preoperative and operative data between the 2 groups.
To compare the time evolution between the 2 treatment
groups, a model for longitudinal data was used.3 Specifically,
a general linear model with first-order autoregressive correla-
tion structure was used. A log-linear model for the variance
was further used to account for variance heterogeneity over
time.4 The data were log transformed to normalize their dis-
tribution, although this could not be fully achieved at later
time occasions because of the high skewness of the data. This
above model was used to test for the significance of the treat-
ment effect over time and to investigate the influence of pos-
sible subject-specific factors, such as electrical defibrillation,
aprotinin administration, and crossclamp time. The effect of
these covariates on CTnI release was allowed to be different
at each time occasion. All computations were performed by
the SAS procedure MIXED (SAS Institute, Inc, Cary, NC).5
Results
Patient profile. One patient in the BCP group was
excluded from analysis. The samples of the patient
were not drawn. Consequently, the analysis included
29 patients in the BCP group. Preoperative and opera-
tive data in both CCP and BCP groups are shown in
Table II. With the exception of age, the groups were
well matched.
Preoperative ejection fraction was equivalent in both
groups.
A preoperative anterior myocardial infarction was
present in 8 patients in the CCP group versus 6 patients
in the BCP group; a preoperative inferior infarction
was present in 11 patients in the CCP group versus 12
patients in the BCP group.
In all but 1 patient in each group, at least one thoracic
artery was used. In the CCP group, 1 patient did not
receive a thoracic artery because of a critical left subcla-
vian artery stenosis, detected on angiographic examina-
tion; in the BCP group 1 patient had only vein grafting
because of a combination of diabetes, marked obesity,
and advanced age. The number of saphenous veins and
distal anastomoses was equivalent in both groups.
The average amount of CCP injected was 1025 ± 308
mL in the CCP group and 254 ± 92 mL in the BCP
group (P = .026; Wilcoxon).
The intensive care unit stay was 28 ± 11.9 hours in the
CCP group and 25 ± 9.1 hours in the BCP group (P = .23).
Five patients in the CCP group and 7 patients in the
BCP group did not require inotropic support. A low
dose (3-6 m g/kg per minute) of a combination of
dopamine and dobutamine was used in 23 patients in
the CCP group and in 18 patients in the BCP group.
Higher doses were required in 4 patients in the CCP
group (7 m g/kg per minute total in 2 patients and 8
m g/kg per minute in 2 patients) and 4 patients in the
BCP group (7 m g/kg per minute in 3 patients and 8
m g/kg per minute in 1 patient).
Norepinephrine (0.025-0.1 m g/kg per minute) was
used as a vasoconstrictor in 4 patients in the CCP group
and in 3 patients in the BCP group. There was no need
for intra-aortic balloon pumping or mechanical support
in any of the patients.
Table II. Patient profile
Variable CCP* BCP* P value†
Mean age (y) 64.7 (7.2) 69.7 (7.4) .01
Male 28 21 .2
Ejection fraction 65.6 (13.6) 67.8 (13.4) .46
Anterior MI 8 6 .77
Inferior MI 11 12 .61
Diabetes 4 6 .5
Hypertension 14 13 1
BSA 1.88 (0.14) 1.83 (0.18) .13
Crossclamp time (min) 46 (12) 47 (11) .45
ECC time (min) 88 (21) 91 (16) .39
LITA 30 28 1
LITA + RITA 5 2 .43
VSM 50 52 .59
Grafts/patient 2.84 ± 0.63 2.76 ± 0.64 .59
MI, Myocardial infarction; BSA, body surface area; ECC, extracorporeal cir-
culation; LITA, left internal thoracic artery; RITA, right internal thoracic
artery; VSM, vena saphena magna.
*Mean (SD) for continuous variables; frequency for discrete variables.
†Wilcoxon test for continuous and ordinal variables, Fisher’s exact test for
binary variables.
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Peak CTnI release was not significantly different
between patients requiring inotropic agents and
patients who did not (19.8 ± 18.2 ng/mL vs 17.4 ± 20.3
ng/mL; P = .70). This indicates that inotropic agents
were mainly used in the treatment of myocardial stun-
ning rather than irreversible damage.
One patient in each group was in chronic atrial fibril-
lation before the operation. Acquired atrial fibrillation
during the hospital stay occurred in 6 patients in the
CCP group and in 8 patients in the BCP group. In the
CCP group, 5 patients experienced the development of
atrial fibrillation during their intensive care unit stay.
Two patients were converted to sinus rhythm with
amiodarone, and 2 patients were converted to sinus
rhythm by propafenon. One patient needed electrical
reconversion. One patient experienced the development
of atrial fibrillation on the ward on postoperative day 4.
He was converted medically with propafenon.
In the BCP group, atrial fibrillation was treated suc-
cessfully with amiodarone in 3 patients and by
propafenon in another 3 patients. Electrical defibrillation
was necessary in 2 patients. All patients were discharged
in sinus rhythm. One patient in the CCP group experi-
enced a transient ischemic attack, which fully recovered
on postoperative day 4. There were no cases of pro-
longed ventilatory support. There was no acquired left
bundle branch block in either group. The angiographic
distribution of coronary lesions did not differ between
the 2 groups. There were no patients in either group with
ECG evidence of perioperative myocardial infarction.
The mean hospital stay was 8.7 ± 1.2 days in the CCP
group and 8.6 ± 0.9 days in the BCP group (P = .68). 
Comparison of CK-MB and CTnI release. This
article reports on perioperative CTnI values in CABG,
with an assay that accurately measures both free and
complexed CTnI. We used a cutoff value for CTnI
(mean ± 2 SD) concentrations of 27.8 ng/mL immedi-
ately after aortic unclamping, 56.0 ng/mL at 6 hours
after unclamping, 51.3 ng/mL at 9 hours after unclamp-
ing, and 40.1 ng/mL at 12 hours after unclamping.
According to those standards, 3 patients in the CCP
and 4 patients in the BCP group had CTnI release
above the cutoff values in at least 1 time point. We
observed a prolonged increase in CTnI, rather than a
distinct peak. In all those patients, CK-MB values were
below the limit of 6% of total CK release.
CK-MB values obtained in the CCP and BCP group
are shown in Table III. At no point in time was there a
significant difference between the 2 treatment groups.
BCP versus CCP. Fig 1 shows the time course of
CTnI concentration for both groups of cardioplegia.
CTnI concentration increased significantly (P < .0001)
from preoperative values starting at aortic unclamping
in both groups. After an initial rise attaining its peak at
Fig 1. Time course of CTnI release according to the type of cardioplegia. Log (CTnI + 1) was plotted as a func-
tion of time (hours). Time zero was chosen as the time of removal of the crossclamp. Error bars represent stan-
dard errors. The P value for the comparison of these 2 profiles is .048.
Table III. CK-MB values
CCP (SD) BCP (SD) P value
Before operation 6.1 (5.4) 7.8 (5.3) .41
After operation 6 hours 22.6 (13.1) 22.3 (8.5) .85
Postoperative day 2 14.8 (6.4) 15.8 (9.0) .66
Postoperative day 3 12.9 (5.6) 15.7 (7.7) .12
Postoperative day 4 12.1 (14.3) 11.7 (6.6) .9
Postoperative day 5 10.8 (15.0) 9.1 (6.6) .64
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6 hours after the operation, the level of CTnI constant-
ly decreased over time. When the overall curves were
considered, there was no clear difference between the 2
profiles (P = .048). When a constant treatment effect
over time was considered, the difference between the 2
treatment groups was not significant (unadjusted, P =
.31; adjusted, P = .59). The adjustment was for the need
of electrical defibrillation, aprotinin administration,
and crossclamp time, with an effect allowed to be dif-
ferent at each time occasion. 
Effect of aprotinin. Because of recent salicylic
acid intake, aprotinin was administered to 16 patients
in the CCP group and 12 patients in the BCP group.
Total CTnI release was significantly lower in the
group of patients receiving aprotinin during the inter-
vention (P = .0003). CTnI levels were significantly
lower in the aprotinin group at 6 hours (11.7 ± 9.2
ng/mL vs 25.3 ± 21.8 ng/mL; P = .002, Wilcoxon)
and at 9 hours (13.1 ± 10.3 ng/mL vs 22.1 ± 19.8
ng/mL; P = .041; Fig 2).
Fig 2. Time course of CTnI release according to whether aprotinin was administered (aprotinin) or not (control).
Log (CTnI + 1) was plotted as a function of time (hours). Time zero was chosen as the time of removal of the
crossclamp. Error bars represent standard errors. Total CTnI release was significantly lower in the aprotinin
group (P = .0003). CTnI concentration at hours 6 and 9 was significantly lower in the aprotinin group.
Fig 3. Time course of CTnI release according to cardiac rhythm recovery. Spont defib, Spontaneous defibrilla-
tion; electr defib, patients requiring electrical defibrillation. Log (CTnI + 1) was plotted as a function of time
(hours). Time zero was chosen as the time of removal of the crossclamp. Error bars represent standard errors.
Overall CTnI release was significantly higher in the electrical defibrillation group (P = .0057). CTnI concentra-
tion at 12 hours was significantly higher in patients needing electrical defibrillation.
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Electrical defibrillation and CTnI release.
Electrical defibrillation was required in 10 patients in
the CCP group and in 12 patients in the BCP group
after removal of the aortic crossclamp to allow sponta-
neous electrical activity to resume. Overall, CTnI
release was significantly higher in the group of patients
who needed electrical defibrillation (P = .0057). CTnI
concentration was significantly higher in the defibrilla-
tion group at 12 hours (11.7 ± 9.8 ng/mL vs 20.3 ± 15.2
ng/mL; P = .005, Wilcoxon; Fig 3).
Main stem lesions. A main stem lesion was present
in 13 patients in the CCP group and in 8 patients in the
BCP group. When the overall curve is considered, CTnI
release was marginally significantly higher in patients
with a main stem lesion in the CCP group when com-
pared with patients who were treated for more distal
lesions with CCP (P = .0473). This difference was not
present in the BCP group (P = .4878; Fig 4).
Crossclamp time. In the multivariate analysis, the
effect of aortic crossclamp time on CTnI release was
significant at 24 hours (P = .015), at 48 hours (P =
.003), at 72 hours (P = .006) , and at 96 hours (P = .009).
Discussion
The use of BCP has gained widespread acceptance.
In a recent national survey, Robinson and colleagues6
reported that BCP was used by 72% of all respondent
surgeons. On the other hand, the numerous methods of
myocardial protection used indicate that there is no
clear evidence of superiority of one method over anoth-
er. Previous clinical studies, comparing BCP and CCP,
have assessed the extent of myocardial damage by ana-
lyzing postoperative ECG changes or release of CK-
MB. However, the sensitivity of ECG changes in
patients undergoing CABG is low.7 Therefore no con-
clusions can be drawn from the fact that there were no
perioperative myocardial infarctions in either group
according to ECG criteria. Also, no difference in CK-
MB release was found between the 2 groups at any
point in time.
This study confirms previous reports, which show a
substantial release of CTnI in elective CABG opera-
tions.8,9 The peak and total CTnI release was not sig-
nificantly different in the BCP and CCP groups. This
suggests that the damage caused to the myocardium in
an unselected group of patients who were undergoing
low-risk primary CABG is similar with both methods
of cardioplegia. Our data confirm 1 previous report by
Caputo and colleagues10 who also found no difference
in CTnI release when comparing a group of patients
receiving BCP with a group of patients receiving CCP
with the use of an operative procedure similar to the
one reported in this article.
However, absolute values of CTnI release are
markedly higher than in their report. Recently,
Katrukha and colleagues2 have reported that the largest
part of CTnI is liberated as a complex, probably with
troponin C, and only a small part of CTnI circulates in
Fig 4. Time course of CTnI release according to the type of cardioplegia and whether a main stem lesion was pre-
sent (+ MS) or absent (no MS). Log (CTnI + 1) was plotted as a function of time (hours). Time zero was chosen
as the time of removal of the crossclamp. Error bars represent standard errors. In the CCP group, the overall curve
of CTnI release was significantly higher in patients with a main stem lesion (P = .0473). In the BCP group, no
difference was observed between patients with or without main stem lesion (P = .7060).
458 Hendrikx et al The Journal of Thoracic and
Cardiovascular Surgery
September 1999
a free form. It should be noted that the ratio of total to
free CTnI varies between patients and within the course
of each episode of myocardial damage. Therefore we
selected a test that allows accurate quantification of
both free and complexed troponin I, because it is
unclear from the data by Caputo and colleagues10
whether the total CTnI release was similar in both
groups or only the part liberated as free form.
Pichon and colleagues,11 on the other hand, have
reported that the total amount of CTnI released was
significantly higher in a CCP group than in a BCP
group. However, their groups differed not only with
respect to the type of cardioplegia but also by the fact
that warm reperfusion was performed only in the BCP
group. This warm controlled reperfusion may be bene-
ficial, not only by better preservation of high-energy
phosphates12 but also by limiting the transsarcolemmal
pH gradient on reperfusion, hence limiting Na+ and
subsequent Ca2+ overload during reperfusion.13
The mechanisms underlying the protective effect of
aprotinin on the myocardium remain unclear. To rule
out an effect of aprotinin on the CTnI assay itself, apro-
tinin (300 KIU/mL) was added to the plasma of
patients with known CTnI elevation in the same range
as the one seen after cardiopulmonary bypass. The con-
centration of aprotinin was chosen to be at the upper
range of measured aprotinin concentrations at the initi-
ation of cardiopulmonary bypass.14 After adding apro-
tinin to the plasma, measured CTnI levels did not
change beyond the dilution factor. Also Wendel and
colleagues15 reported lower cardiac troponin T levels in
patients undergoing cardiopulmonary bypass receiving
high-dose aprotinin therapy. Cardiac operations with
cardiopulmonary bypass are associated with the release
of various inflammatory mediators such as tumor
necrosis factor a . Integrin CD11b is a neutrophil sur-
face adhesive glycoprotein that becomes rapidly and
irreversibly unregulated by tumor necrosis factor a .
Hill and colleagues16 have reported that even low-dose
aprotinin has a significant effect in blunting systemic
tumor necrosis factor a release and neutrophil integrin
CD11b up-regulation. Furthermore, full-dose aprotinin
has been reported to reduce the cardiopulmonary-
induced release of the proinflammatory cytokine, inter-
leukin-6,17 and enhance the release of the endogenous
anti-inflammatory cytokine, interleukin-10.18
However, this cannot be the only mechanism because
the protective action of aprotinin was shown both in the
isolated rat heart subjected to global ischemia19 and in
a model of regional ischemia in the dog.20 Oxygen free
radicals, derived in part from neutrophils and formed
particularly during the reperfusion phase, may con-
tribute to membrane damage by activation of proteases.
Treatment with aprotinin would adequately prevent a
hydrogen peroxide–induced fall in catalase activity and
hence reduce the magnitude of cytotoxicity.21 This
would ultimately result in better preservation of selec-
tive sarcolemmal permeability and reduced cellular
calcium overload.
Recently, the results of the first international multi-
center trial, designed to address the graft occlusion
problem associated with aprotinin administration, with
graft angiography (IMAGE trial), have been reported.22
The probability of early vein graft occlusion was
increased by aprotinin (15.4% of the patients receiving
aprotinin versus 10.9% of patients receiving placebo; P
= .03), whereas thoracic artery patency was not affect-
ed. Subanalysis revealed several risk factors for early
graft failure: aprotinin definitely promotes graft occlu-
sion in women (5-fold increase over placebo), in smaller
vessels (<1.5 mm), and in patients with poor-quality
distal vessels. Therefore the routine use in coronary
surgical procedures should not be advocated. However,
careful selection of patients based on the known risk
factors of early graft failure associated with aprotinin
use would allow a subgroup of patients to benefit from
the protective action of aprotinin during ischemic arrest.
CTnI concentration was significantly lower at 12
hours after unclamping in patients not requiring elec-
trical defibrillation, which is consistent with a previous
report by Pichon and colleagues.11 However, the strik-
ing difference is that, in their CCP group, all but 1
patient of 35 required electrical defibrillation, whereas
in the BCP group 17 patients did not. In this study, the
need for electrical defibrillation was evenly distributed
between the BCP and the CCP group: 12 patients in the
BCP group and 10 patients in the CCP group required
electrical defibrillation. This suggests that the reduced
need for electrical defibrillation observed by Pichon
and colleagues11 is a consequence of warm reperfusion,
rather than the type of cardioplegic solution used. 
CTnI release was significantly higher in the CCP
group in patients with a critical main stem lesion. In the
BCP group, CTnI release was similar whether a main
stem lesion was present or not. It would indicate
improved protection with BCP in the subgroup of main
stem patients. This may be explained by the fact that
perfusion, distal to coronary stenoses, was shown to be
improved with blood as opposed to CCP.23
In this study, the effect of aortic crossclamp time was
significant at a few time points. This effect, however,
was not as strong as could be expected. This may be
explained by the fact that myocardial damage in
patients undergoing CABG is multifactorial. The
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anatomy of the coronary lesions may variably influence
the efficacy of antegrade cardioplegia.
Conclusion 
Rising levels of CTnI are found in all patients under-
going CABG, with peak concentrations at 6 hours after
aortic unclamping. This specific and sensitive marker
does not detect significant difference in myocardial pro-
tection between antegrade cold CCP and antegrade cold
BCP in patients with preserved left ventricular function
undergoing elective first-time CABG. High-dose apro-
tinin administration was associated with lower CTnI
release, suggesting protective action against ischemic
injury. Electrical defibrillation resulted in higher CTnI
release in both CCP and BCP groups. Higher CTnI lev-
els were observed in patients with a main stem lesion
only in the CCP group. This would indicate improved
protection with BCP in this subgroup of patients.
We thank Drs J. Kortleven and V. Peeters, for their help
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